130 related articles for article (PubMed ID: 23636143)
21. [Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].
Blons H; Laurent-Puig P
Bull Cancer; 2009 Dec; 96 Suppl():S47-56. PubMed ID: 20034870
[TBL] [Abstract][Full Text] [Related]
22. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.
Perkins G; Lièvre A; Ramacci C; Méatchi T; de Reynies A; Emile JF; Boige V; Tomasic G; Bachet JB; Bibeau F; Bouché O; Penault-Llorca F; Merlin JL; Laurent-Puig P
Int J Cancer; 2010 Sep; 127(6):1321-31. PubMed ID: 20049837
[TBL] [Abstract][Full Text] [Related]
23. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
24. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
25. c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
Li Y; Wang J; Gao X; Han W; Zheng Y; Xu H; Zhang C; He Q; Zhang L; Li Z; Zhou D
PLoS One; 2014; 9(11):e113186. PubMed ID: 25427200
[TBL] [Abstract][Full Text] [Related]
26. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
[TBL] [Abstract][Full Text] [Related]
27. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
28. KRAS mutations: analytical considerations.
Herreros-Villanueva M; Chen CC; Yuan SS; Liu TC; Er TK
Clin Chim Acta; 2014 Apr; 431():211-20. PubMed ID: 24534449
[TBL] [Abstract][Full Text] [Related]
29. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.
Laurent-Puig P; Pekin D; Normand C; Kotsopoulos SK; Nizard P; Perez-Toralla K; Rowell R; Olson J; Srinivasan P; Le Corre D; Hor T; El Harrak Z; Li X; Link DR; Bouché O; Emile JF; Landi B; Boige V; Hutchison JB; Taly V
Clin Cancer Res; 2015 Mar; 21(5):1087-97. PubMed ID: 25248381
[TBL] [Abstract][Full Text] [Related]
31. Mutation detection in KRAS Exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries.
Bjørheim J; Minarik M; Gaudernack G; Ekstrøm PO
Anal Biochem; 2002 May; 304(2):200-5. PubMed ID: 12009696
[TBL] [Abstract][Full Text] [Related]
32. Ras gene activation and epidermal growth factor receptor expression in human colon cancer.
Ravikumar TS; Wolf B; Cocchiaro C; D'Emilia J; Steele G
J Surg Res; 1989 Nov; 47(5):418-22. PubMed ID: 2682005
[TBL] [Abstract][Full Text] [Related]
33. Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
Prewett M; Bassi R; Paz K; Amatulli M; Deevi D; Li H; Wang S; Witte L; Samakoglu S; Tonra JR
Anticancer Res; 2011 Jun; 31(6):2149-60. PubMed ID: 21737635
[TBL] [Abstract][Full Text] [Related]
34. The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.
Lièvre A; Artru P; Guiu M; Laurent-Puig P; Merlin JL; Sabourin JC; Viguier J; Bastie A; Seronde A; Ducreux M
Eur J Cancer; 2013 Jun; 49(9):2126-33. PubMed ID: 23473612
[TBL] [Abstract][Full Text] [Related]
35. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells.
Zeng M; Kikuchi H; Pino MS; Chung DC
PLoS One; 2010 Jun; 5(6):e10966. PubMed ID: 20532039
[TBL] [Abstract][Full Text] [Related]
37.
Chung WJ; Daemen A; Cheng JH; Long JE; Cooper JE; Wang BE; Tran C; Singh M; Gnad F; Modrusan Z; Foreman O; Junttila MR
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10947-E10955. PubMed ID: 29203670
[No Abstract] [Full Text] [Related]
38. [Personalized therapy of gastrointestinal cancers--possibilities and limitations].
Wichert Gv; Adler G; Seufferlein T
Dtsch Med Wochenschr; 2010 Aug; 135(34-35):1687-91. PubMed ID: 20721844
[TBL] [Abstract][Full Text] [Related]
39. RAS mutations in human cancers: Roles in precision medicine.
Murugan AK; Grieco M; Tsuchida N
Semin Cancer Biol; 2019 Dec; 59():23-35. PubMed ID: 31255772
[TBL] [Abstract][Full Text] [Related]
40. The mystery of oncogenic KRAS: Lessons from studying its wild-type counter part.
Chang YI; Damnernsawad A; Kong G; You X; Wang D; Zhang J
Small GTPases; 2017 Oct; 8(4):233-236. PubMed ID: 27449543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
